{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:28:41Z","timestamp":1790015321515,"version":"4.0.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41433-018-0315-9","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T14:40:29Z","timestamp":1546612829000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy"],"prefix":"10.1038","volume":"33","author":[{"given":"Diego","family":"Strianese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"315_CR1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","volume":"142","author":"JA Garrity","year":"2006","unstructured":"Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147\u201353.","journal-title":"Am J Ophthalmol"},{"key":"315_CR2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1089\/thy.2007.0185","volume":"17","author":"TK Khoo","year":"2007","unstructured":"Khoo TK, Bahn RS. Pathogenesis of Graves\u2019 ophthalmopathy: the role of autoantibodies. Thyroid. 2007;17:1013\u20138.","journal-title":"Thyroid"},{"key":"315_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/clpt.2012.10","volume":"91","author":"RS Bahn","year":"2012","unstructured":"Bahn RS. Autoimmunity and Graves\u2019 disease. Clin Pharmacol Ther. 2012;91:577\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"315_CR4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-6217-0_12","volume":"785","author":"D Amsen","year":"2013","unstructured":"Amsen D, Backer RA, Helbig C. Decisions on the road to memory. Adv Exp Med Biol. 2013;785:107\u201320.","journal-title":"Adv Exp Med Biol"},{"key":"315_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","volume":"247","author":"MJ Shlomchik","year":"2012","unstructured":"Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247:52\u201363.","journal-title":"Immunol Rev"},{"key":"315_CR6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","volume":"131","author":"K Pieper","year":"2013","unstructured":"Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol. 2013;131:959\u201371.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"315_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-065X.2010.00938.x","volume":"237","author":"Taketoshi Yoshida","year":"2010","unstructured":"Yoshida T, Mei H, D\u00f6rner T, Hiepe F, Radbruch A, Fillatreau S, et al. Memory B and memory plasma cells. Immunol Rev. 2010;237:117\u201339.","journal-title":"Immunological Reviews"},{"issue":"10","key":"315_CR8","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","volume":"178","author":"Martin Duddy","year":"2007","unstructured":"Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178:6092\u20139.","journal-title":"The Journal of Immunology"},{"key":"315_CR9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1084\/jem.20041185","volume":"200","author":"Y Nie","year":"2004","unstructured":"Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med. 2004;200:1145\u201356.","journal-title":"J Exp Med"},{"issue":"4","key":"315_CR10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","volume":"171","author":"Giuliana Cassese","year":"2003","unstructured":"Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171:1684\u201390.","journal-title":"The Journal of Immunology"},{"key":"315_CR11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/thy.1999.9.305","volume":"9","author":"D Yang","year":"1999","unstructured":"Yang D, Hiromatsu Y, Hoshino T, Inoue Y, Itoh K, Nonaka K. Dominant infiltration of T(H)1-type CD4+T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid. 1999;9:305\u201310.","journal-title":"Thyroid"},{"key":"315_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2249.1998.00613.x","volume":"112","author":"G F\u00f6rster","year":"1998","unstructured":"F\u00f6rster G, Otto E, Hansen C, Ochs K, Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol. 1998;112:427\u201334.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"315_CR13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2249.1997.4491347.x","volume":"109","author":"A. PAPPA","year":"1997","unstructured":"Pappa A, Calder V, Ajjan R, Fells P, Ludgate M, Weetman AP, et al. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol. 1997;109:362\u20139.","journal-title":"Clinical and Experimental Immunology"},{"key":"315_CR14","unstructured":"de Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 1993;77:1120\u20134."},{"key":"315_CR15","first-page":"1194","volume":"85","author":"Y Hiromatsu","year":"2000","unstructured":"Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85:1194\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR16","first-page":"776","volume":"85","author":"JP Aniszewski","year":"2000","unstructured":"Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","volume":"35","author":"SM McLachlan","year":"2014","unstructured":"McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35:59\u2013105.","journal-title":"Endocr Rev"},{"key":"315_CR18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2012-4309","volume":"98","author":"G Barbesino","year":"2013","unstructured":"Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247\u201355.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","volume":"26","author":"S Iyer","year":"2012","unstructured":"Iyer S, Bahn R. Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26:281\u20139.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"315_CR20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","volume":"342","author":"A Feliciello","year":"1993","unstructured":"Feliciello A, Porcellini A, Ciullo I, Bonavolont\u00e0 G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue. Lancet. 1993;342:337\u20138.","journal-title":"Lancet"},{"key":"315_CR21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/thy.1993.3.297","volume":"3","author":"AE Heufelder","year":"1993","unstructured":"Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves\u2019 ophthalmopathy and pretibial dermopathy. Thyroid. 1993;3:297\u2013300.","journal-title":"Thyroid"},{"key":"315_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/thy.1998.8.193","volume":"8","author":"RS Bahn","year":"1998","unstructured":"Bahn RS, Dutton CM, Joba W, Heufelder AE. Thyrotropin receptor expression in cultured Graves\u2019 orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid. 1998;8:193\u20136.","journal-title":"Thyroid"},{"key":"315_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","volume":"52","author":"MN Gerding","year":"2000","unstructured":"Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves\u2019 ophthalmopathy. Clin Endocrinol. 2000;52:267\u201371.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"315_CR24","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"Shanli Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181:4397\u2013405.","journal-title":"The Journal of Immunology"},{"key":"315_CR25","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","volume":"14","author":"MM Chitnis","year":"2008","unstructured":"Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008;14:6364\u201370.","journal-title":"Clin Cancer Res"},{"key":"315_CR26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","volume":"26","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Heged\u00fcs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:291\u2013302.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"315_CR27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","volume":"55","author":"Y Wang","year":"2014","unstructured":"Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55:1735\u201348.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"315_CR28","doi-asserted-by":"crossref","unstructured":"van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2012;97:E400\u2013408.","DOI":"10.1210\/jc.2011-2697"},{"issue":"11","key":"315_CR29","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1167\/iovs.05-0605","volume":"46","author":"Stephen E. Feldon","year":"2005","unstructured":"Feldon SE, Park DJ, O'Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves\u2019 ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46:3913\u201321.","journal-title":"Investigative Opthalmology & Visual Science"},{"key":"315_CR30","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1167\/iovs.13-12741","volume":"54","author":"AE Kuriyan","year":"2013","unstructured":"Kuriyan AE, Woeller CF, O\u2019Loughlin CW, Phipps RP, Feldon SE. Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype. Invest Ophthalmol Vis Sci. 2013;54:7370\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"315_CR31","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1167\/iovs.08-2328","volume":"50","author":"Catherine J. Hwang","year":"2009","unstructured":"Hwang CJ1, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009;50:2262\u20138.","journal-title":"Investigative Opthalmology & Visual Science"},{"key":"315_CR32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U","volume":"32","author":"L Koumas","year":"2002","unstructured":"Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32:477\u201385.","journal-title":"Eur J Immunol"},{"issue":"1","key":"315_CR33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","volume":"87","author":"Terry J. Smith","year":"2002","unstructured":"Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385\u201392.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"315_CR34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"GM Lehmann","year":"2008","unstructured":"Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18:959\u201365.","journal-title":"Thyroid"},{"issue":"5","key":"315_CR35","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2013-1149","volume":"98","author":"Adina F. Turcu","year":"2013","unstructured":"Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153\u20139.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"39","key":"315_CR36","doi-asserted-by":"crossref","first-page":"26447","DOI":"10.1074\/jbc.M109.003616","volume":"284","author":"Lei Zhang","year":"2009","unstructured":"Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, et al. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem. 2009;284:26447\u201355.","journal-title":"Journal of Biological Chemistry"},{"key":"315_CR37","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"315_CR38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/thy.2010.0123","volume":"21","author":"Clementine J.J. van Zeijl","year":"2011","unstructured":"van Zeijl CJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, et al. Thyrotropin receptor-stimulating Graves\u2019 disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves\u2019 ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid. 2011;21:169\u201376.","journal-title":"Thyroid"},{"key":"315_CR39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/JME-11-0006","volume":"46","author":"S Kumar","year":"2011","unstructured":"Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves\u2019 ophthalmopathy. J Mol Endocrinol. 2011;46:155\u201363.","journal-title":"J Mol Endocrinol"},{"key":"315_CR40","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1016\/S0021-9258(19)76555-7","volume":"263","author":"PJ Smith","year":"1988","unstructured":"Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS. Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem. 1988;263:9402\u20138.","journal-title":"J Biol Chem"},{"key":"315_CR41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.exer.2012.11.014","volume":"107","author":"Pingqian Zhao","year":"2013","unstructured":"Zhao P, Deng Y, Gu P, Wang Y, Zhou H, Hu Y, et al. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp Eye Res. 2013;107:65\u201373.","journal-title":"Experimental Eye Research"},{"key":"315_CR42","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2006-10-050633","volume":"110","author":"I Hers","year":"2007","unstructured":"Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS\/PI3Kalpha pathway. Blood. 2007;110:4243\u201352.","journal-title":"Blood"},{"key":"315_CR43","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/mend.14.6.0487","volume":"14","author":"CM Boney","year":"2000","unstructured":"Boney CM, Gruppuso PA, Faris RA, Frackelton AR. The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes. Mol Endocrinol. 2000;14:805\u201313.","journal-title":"Mol Endocrinol"},{"key":"315_CR44","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353:1711\u201323.","journal-title":"N Engl J Med"},{"key":"315_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ecl.2009.01.004","volume":"38","author":"J Dickinson","year":"2009","unstructured":"Dickinson J, Perros P. Thyroid-associated orbitopathy: who and how to treat. Endocrinol Metab Clin North Am. 2009;38:373\u201388. ix","journal-title":"Endocrinol Metab Clin North Am"},{"key":"315_CR46","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2005;90:5234\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","volume":"61","author":"S Aktaran","year":"2007","unstructured":"Aktaran S, Akarsu E, Erba\u011fci I, Araz M, Okumu\u015f S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy. Int J Clin Pract. 2007;61:45\u201351.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"315_CR48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2265.1987.tb00836.x","volume":"27","author":"C. MARCOCCI","year":"1987","unstructured":"Marcocci C, Bartalena L, Panicucci M, Marconcini C, Cartei F, Cavallacci G, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves\u2019 ophthalmopathy: a comparative study. Clin Endocrinol. 1987;27:33\u201342.","journal-title":"Clinical Endocrinology"},{"issue":"12","key":"315_CR49","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L. Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97:4454\u201363.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"315_CR50","first-page":"3562","volume":"86","author":"Claudio Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562\u20137.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"315_CR51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","volume":"166","author":"Claudio Marcocci","year":"2012","unstructured":"Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166:247\u201353.","journal-title":"European Journal of Endocrinology"},{"issue":"7","key":"315_CR52","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/thy.2015.0061","volume":"25","author":"Eleonora Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, et al. Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves\u2019 orbitopathy. Thyroid. 2015;25:846\u201350.","journal-title":"Thyroid"},{"key":"315_CR53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR54","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1089\/thy.2014.0533","volume":"25","author":"Z Giotaki","year":"2015","unstructured":"Giotaki Z, Fountas A, Tsirouki T, Bargiota A, Tigas S, Tsatsoulis A. Adrenal reserve following treatment of Graves\u2019 orbitopathy with intravenous glucocorticoids. Thyroid. 2015;25:462\u20133.","journal-title":"Thyroid"},{"key":"315_CR55","first-page":"341","volume":"122","author":"T Gasi\u0144ska","year":"2012","unstructured":"Gasi\u0144ska T, Borowska A, Wichary H, Dec R. Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves\u2019 ophthalmopathy. Pol Arch Med Wewn. 2012;122:341\u20137.","journal-title":"Pol Arch Med Wewn"},{"key":"315_CR56","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168\u201399.","journal-title":"Endocr Rev"},{"issue":"20","key":"315_CR57","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"Mark F. Prummel","year":"1989","unstructured":"Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med. 1989;321:1353\u20139.","journal-title":"New England Journal of Medicine"},{"key":"315_CR58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/sj.eye.6702393","volume":"20","author":"PA Meyer","year":"2006","unstructured":"Meyer PA. Avoiding surgery for thyroid eye disease. Eye. 2006;20:1171\u20137.","journal-title":"Eye"},{"key":"315_CR59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1530\/acta.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol. 1990;122:8\u201312.","journal-title":"Acta Endocrinol"},{"key":"315_CR60","doi-asserted-by":"crossref","unstructured":"Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM, et al. Protocol for the combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials. 2008;9:6.","DOI":"10.1186\/1745-6215-9-6"},{"key":"315_CR61","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5301\/ejo.5000463","volume":"24","author":"NT Chalvatzis","year":"2014","unstructured":"Chalvatzis NT, Tzamalis AK, Kalantzis GK, El-Hindy N, Dimitrakos SA, Potts MJ. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. Eur J Ophthalmol. 2014;24:953\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"315_CR62","doi-asserted-by":"crossref","unstructured":"Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u00d72 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:299\u2013309.","DOI":"10.1016\/S2213-8587(18)30021-4"},{"issue":"2","key":"315_CR63","first-page":"247","volume":"86","author":"Xiaozhen Ye","year":"2016","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol (Oxf). 2017;86:247\u201355.","journal-title":"Clinical Endocrinology"},{"key":"315_CR64","unstructured":"Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6:1\u20136."},{"key":"315_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/128903","volume":"2014","author":"Diego Strianese","year":"2014","unstructured":"Strianese D, Iuliano A, Ferrara M, Comune C, Baronissi I, Napolitano P, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014:128903.","journal-title":"Journal of Ophthalmology"},{"key":"315_CR66","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101\u2013R109.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"315_CR67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"Mario Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422\u201331.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"315_CR68","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:432\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"315_CR69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"315_CR70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/01676830903104611","volume":"28","author":"M Salvi","year":"2009","unstructured":"Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit. 2009;28:251\u20135.","journal-title":"Orbit"},{"key":"315_CR71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2265.2009.03762.x","volume":"72","author":"GE Krassas","year":"2010","unstructured":"Krassas GE, Stafilidou A, Boboridis KG. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol. 2010;72:853\u20135.","journal-title":"Clin Endocrinol"},{"key":"315_CR72","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/IOP.0b013e31828956a8","volume":"30","author":"AJ Gess","year":"2014","unstructured":"Gess AJ, Silkiss RZ. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30:e11\u201313.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"315_CR73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras JV, Alvarez-L\u00f3pez A, G\u00f3mez EC. Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30:162\u20137.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"315_CR74","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/IOP.0000000000000730","volume":"33","author":"A Sy","year":"2017","unstructured":"Sy A, Eliasieh K, Silkiss RZ. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2017;33:e55\u2013e57.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"315_CR75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"Jose V. Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, et al. Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves\u2032 orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390.","journal-title":"American Journal of Ophthalmology"},{"key":"315_CR76","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye. 2005;19:1286\u20139.","journal-title":"Eye"},{"key":"315_CR77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","volume":"30","author":"R Ayabe","year":"2014","unstructured":"Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30:415\u20139.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"315_CR78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","volume":"24","author":"OM Durrani","year":"2005","unstructured":"Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24:117\u20139.","journal-title":"Orbit"},{"key":"315_CR79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ICU.0000000000000402","volume":"28","author":"D Strianese","year":"2017","unstructured":"Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol. 2017;28:505\u201313.","journal-title":"Curr Opin Ophthalmol"},{"issue":"4S Suppl 1","key":"315_CR80","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/IOP.0000000000001131","volume":"34","author":"D Strianese","year":"2018","unstructured":"Strianese D. Efficacy and safety of immunosuppressive agents for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S56\u2013S59.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"18","key":"315_CR81","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"Terry J. Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"315_CR82","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/IOP.0000000000001080","volume":"34","author":"Louise A. Mawn","year":"2018","unstructured":"Mawn LA, Dolman PJ, Kazim M, Strianese D, Genol I, Chong KKL, et al. Soft tissue metrics in thyroid eye disease: an International Thyroid Eye Disease society reliability study. Ophthalmic Plast Reconstr Surg. 2018;34:544\u201346.","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"issue":"2","key":"315_CR83","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/IOP.0000000000000437","volume":"32","author":"Chad M. Bingham","year":"2016","unstructured":"Bingham CM, Sivak-Callcott JA, Gurka MJ, Nguyen J, Hogg JP, Feldon SE, et al. Axial globe position measurement: a prospective multicenter study by the International Thyroid Eye Disease Society. Ophthalmic Plast Reconstr Surg. 2016;32:106\u201312.","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"issue":"2","key":"315_CR84","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ophtha.2011.07.011","volume":"119","author":"Peter J. Dolman","year":"2012","unstructured":"Dolman PJ, Cahill K, Czyz CN, Douglas RS, Elner VM, Feldon S, et al. Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology. 2012;119:382\u20139.","journal-title":"Ophthalmology"},{"key":"315_CR85","doi-asserted-by":"crossref","unstructured":"Strianese D, Piscopo R, Elefante A, Napoli M, Comune C, Baronissi I, et al. Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study. BMC Ophthalmol. 2013;13:21.","DOI":"10.1186\/1471-2415-13-21"},{"key":"315_CR86","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11845-016-1542-3","volume":"186","author":"P Grassi","year":"2017","unstructured":"Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolont\u00e0 G. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids? Ir J Med Sci. 2017;186:647\u201352.","journal-title":"Ir J Med Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0315-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:10Z","timestamp":1684616770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0315-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0315-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"18 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}